Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma

Mayo Clinic Proceedings

Volumn 70, Issue 9, 1995, Pages 869-879

  Eric Wang, Chin Yao ^a,b   Schroeter, Arnold L ^a,b   Su, W P Daniel ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

acquired immunodeficiency syndrome; AIDS; AIDS KS; FGF; fibroblast growth factor; HIV; HPV; human immunodeficiency virus; human papillomaviruses; I AIDS related Kaposi's sarcoma; IL; interleukin; Kaposi's sarcoma; KS; KS associated with HIV; KS HIV; messenger RNA; mRNA

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; DAUNORUBICIN; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; RETINOIC ACID; TENIPOSIDE; TETRADECYL SULFATE SODIUM; TRANSFORMING GROWTH FACTOR BETA; VINBLASTINE; VINCRISTINE; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ALOPECIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL FEATURE; DRUG INDUCED DISEASE; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NEUTROPENIA; ONCOGENE; REVIEW; RISK FACTOR; SKIN CANCER; TREATMENT OUTCOME;

EID: 0029103355     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/70.9.869     Document Type: Review

References (151)

1. Kaposi's sarcoma
2. Epidemiology of Kaposi's sarcoma
3. Acquired immunodeficiency syndrome: clinicopathologic study of 56 autopsies
4. Endothelial transdifferentiated phenotype and cell-cycle kinetics of AIDS-associated Kaposi sarcoma cells
5. Culture and properties of cells derived from Kaposi sarcoma
6. Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men
7. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men
8. A composite risk score for Kaposi's sarcoma (KS) based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population [abstract]
9. Surgical oncology on AIDS and cryosurgery on epidemic Kaposi's sarcoma [abstract]
10. Coexistent oral cryptococcosis and Kaposi's sarcoma in acquired immunodeficiency syndrome
11. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma
12. Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug users as the main group affected by HIV infection
13. Geographic and birth cohort associations of Kaposi's sarcoma among homosexual men in Canada
14. Aggressive Kaposi's sarcoma and campylobacter bacteremia in a female with transfusion associated AIDS
15. Kaposi's sarcoma and non-Hodgkin's lymphoma in European AIDS cases: no excess risk of Kaposi's sarcoma in Mediterranean countries
16. Geographic and birth cohort associations of Kaposi's sarcoma among homosexual men in Canada [abstract]
17. Dermatologic manifestations of human immunodeficiency virus infection
18. Epidemiology of AIDS-related Kaposi's sarcoma (KS): an update [abstract]
19. Epidemiological & clinical features of Kaposi's sarcoma in adults in Zambia [abstract]
20. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?
21. AIDS-related Kaposi's sarcoma (KS) in the United States: matching AIDS and cancer registries [abstract]
22. HPV-16-related DNA sequences in Kaposi's sarcoma
23. Is risk of Kaposi's sarcoma in AIDS patients in Britain increased if sexual partners came from United States or Africa?
24. A phase II clinical trial of DaunoXome (VS103, liposomal daunorubicin) in Kaposi's sarcoma of AIDS patients [abstract]
25. Kaposi sarcoma in HIV patients [abstract]
26. Kaposi's sarcoma (KS) associated with AIDS: a clinical study of 200 patients [abstract]
27. Kaposi's sarcoma (KS) in women with AIDS [abstract]
28. Acute respiratory failure (ARF) needing controlled ventilation (CV) in AIDS patients with pulmonary Kaposi's sarcoma (KS): short-term favorable evolution due to steroids and chemotherapy; the East Paris CISIH Group [abstract]
29. The epidemiology of classic, African, and immunosuppressed Kaposi's sarcoma
30. AIDS-associated Kaposi's sarcoma in Romanian children
31. Latency period to the development of childhood AIDS-associated Kaposi's sarcoma (KS) in African children [abstract]
32. Photodynamic therapy (PDT) in AIDS related cutaneous Kaposi's sarcoma (KS) [abstract]
33. AIDS-associated Kaposi's sarcoma (KS) in a couple: an additional evidence of KS as a sexually transmissible infection [abstract]
34. Kaposi's sarcoma (KS) in AIDS cases: predictive factors [abstract]
35. Infectious aetiology of Kaposi's sarcoma: evaluation of Australian evidence [abstract]
36. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine: Zidovudine Epidemiology Study Group
37. A collaborative study on Kaposi's sarcoma and non-Hodgkin's lymphoma among AIDS patients in Italy [abstract]
38. Epidemic Kaposi's sarcoma: evaluation of prognostic factors and survival [abstract]
39. Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS
40. Comparison of clinical and epidemiological aspects of endemic and AIDS-associated Kaposi's sarcoma, Kinshasa, Zaire [abstract]
41. Risk of Kaposi sarcoma (K.S.) after the first opportunistic infection (O.I.) in a cohort of homosexuals [abstract]
42. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy
43. Sexual behavior and an infectious agent as risk factors for Kaposi's sarcoma among homosexual men in a San Francisco cohort [abstract]
44. Conjunctival microvasculopathy and Kaposi's sarcoma in patients with AIDS [letter]
45. Kaposi's sarcoma associated with AIDS: analysis of predictive factors for survival [abstract]
46. Heterogeneity, ploidy and proliferation of spindle cells in HIV-associated and endemic Kaposi's sarcoma [abstract]
47. Naive and memory T cell subsets, activation markers (CD25, CD69), and NK cells in AIDS-related Kaposi's sarcoma [abstract]
48. HIV and the mimicry-hypothesis of HLA-association: HLA-antigens in HIV-1 infection and Kaposi's sarcoma [abstract]
49. Antibodies to HPV 16-E7 protein in patients with AIDS-Kaposi's sarcoma [abstract]
50. Detection of HPV-16 related DNA sequences in Kaposi's sarcoma tissues and derived cell cultures [abstract]
51. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
52. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence
53. Absence of monoclonal antibody detectable Kaposi sarcoma-specific antigens on lesion-derived cultured cells
54. The concurrent presence of systemic disease pathogens and cutaneous Kaposi's sarcoma in the same lesion: Histoplasma capsulatum and Kaposi's sarcoma coexisting in a single skin lesion in a patient with AIDS
55. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor
56. Similarities and differences between cell cultures derived from AIDS-associated and classic Kaposi's sarcoma biopsies [abstract]
57. AIDS-related malignancies: the emerging epidemic
58. In vivo expression of growth factors and cytokines in AIDS associated Kaposi's sarcoma (AIDS-KS) tumors [abstract]
59. Elevated serum interleukin 6 (IL-6) levels are associated with the development of AIDS-Kaposi's sarcoma (AIDS-KS) [abstract]
60. HIV-1 infection and modulation of cytokine and growth factor expression in Kaposi's sarcoma-derived cells in vitro
61. HIV-1 infection and modulation of cytokine and growth factor expression in AIDS-Kaposi's sarcoma derived cells [abstract]
62. Pathogenesis of HIV-related malignancies
63. HIV-tat increases IL-6 production by and proliferation of AIDS-KS derived cells [abstract]
64. Expression of int-2 oncogene in Kaposi's sarcoma lesions
65. TGF beta and FGF-like growth factors involved in the pathogenesis of AIDS-associated Kaposi's sarcoma
66. Expression of fibroblast growth factors (FGFs) and their receptors in AIDS-associated Kaposi's sarcoma lesions [abstract]
67. Kaposi's sarcoma: its “oncogenes” and growth factors
68. Supernatants of acquired immunodeficiency syndrome-related Kaposi's sarcoma cells induce endothelial cell chemotaxis and invasiveness
69. Fibroblast growth factor gene expression in AIDS-Kaposi's sarcoma detected by in situ hybridization
70. Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells: evidence that this pathway is important in Kaposi cell growth
71. Correlation of oncostatin M secretion by human retrovirus-infected cells with potent growth stimulation of cultured spindle cells from AIDS-Kaposi's sarcoma
72. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells
73. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M
74. Oncostatin-M increases interleukin-6 expression and proliferation of AIDS-Kaposi sarcoma (AIDS-KS) cell lines [abstract]
75. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance
76. Recombinant platelet factor 4 (rPF4) and a non-heparin binding derivative inhibit AIDS-Kaposi sarcoma derived cell lines [abstract]
77. An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family
78. Expression of the int-2 oncogene in AIDS-KS lesions [abstract]
79. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma
80. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice
81. Interferon and other biologic agents for the treatment of Kaposi's sarcoma
82. Chromosome instability as a cause of AIDS-related tumors [abstract]
83. Impact of radiotherapy on oral AIDS-related Kaposi's sarcoma [abstract]
84. Treatment of oral Kaposi's sarcoma with a sclerosing agent in AIDS patients: a preliminary study
85. Intralesional interferon alfa 2A in the treatment of oral lesions of Kaposi's sarcoma in homosexual AIDS patients [abstract]
86. Immunoelectron microscopy shows an atypical pattern and a quantitative shift of collagens type I, III and VI in oral Kaposi's sarcoma of AIDS
87. Four days continuous infusion chemotherapy for AIDS associated aggressive Kaposi sarcoma (KS): a preliminary report [abstract]
88. Bronchopulmonary Kaposi's sarcoma in patients with AIDS
89. Prognostic factors for survival in AIDS patients with pulmonary Kaposi's sarcoma (KS) treated by chemotherapy (CT) [abstract]
90. Treatment of pulmonary Kaposi's sarcoma (PKS) with combination chemotherapy [abstract]
91. Steroid-related bronchopulmonary Kaposi sarcoma in a homosexual man with AIDS [abstract]
92. Extensive mucosal Kaposi sarcoma with exudative enteropathy in 2 AIDS patients [abstract]
93. Kaposi's sarcoma of the gallbladder
94. Acquired immunodeficiency syndrome-related Kaposi's sarcoma of the male genitalia: management with radiation therapy
95. Hepatosplenic AIDS-related Kaposi's sarcoma
96. Kaposi's sarcoma of the head and neck in acquired immunodeficiency syndrome
97. Primary intraosseous AIDS-associated Kaposi's sarcoma: report of two cases with initial jaw involvement
98. Hypothyroidism due to destruction of the thyroid by Kaposi's sarcoma
99. Kaposi's sarcoma in the bone marrow of a patient with AIDS
100. Efficacy and toxicity of liposomal doxorubicin in advanced AIDS-related Kaposi sarcoma (KS): an open study [abstract]
101. Myco-plasma penetrans infection associated with Kaposi's sarcoma in male homosexuals with AIDS [abstract]
102. Kaposi's sarcoma presenting as a sign of AIDS in Zairian children [abstract]
103. Propagation and properties of Kaposi's sarcoma-derived cell lines obtained from patients with AIDS: similarity of cultured cells to smooth muscle cells
104. Distribution of basement membrane-associated heparan sulfate proteoglycan in idiopathic and AIDS-associated Kaposi's sarcoma
105. Fibroblastic and monocytic spindle cells in HIV-related and endemic Kaposi's sarcoma (KS) [abstract]
106. Cryotherapy of AIDS-related Kaposi's sarcoma [abstract]
107. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial
108. Soft x-ray therapy for AIDS-associated Kaposi's sarcoma [abstract]
109. Intralesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma
110. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome: a clinical trial to evaluate efficacy and discomfort associated with infection
111. AIDS-associated Kaposi's sarcoma
112. Radiotherapy (RT) for broncho-pulmonary AIDS related Kaposi's sarcoma (KS) [abstract]
113. Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma
114. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group
115. Liposomal-encapsulated cytotoxic agent daunorubicin (LD) versus conventional three-drug chemotherapy (CC) in AIDS patients with Kaposi's sarcoma (KS)–preliminary results [abstract]
116. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial
117. The effect of daunorubicin (Dauno) or doxorubicin (Doxo) on epidemic Kaposi's sarcoma (EKS) derived cell cultures [abstract]
118. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma
119. Use of G-CSF in the management of chemotherapy-induced neutropenia in patients with advanced-stage Kaposi-sarcoma [abstract]
120. Liposomal doxorubicin—a new formulation for the treatment of Kaposi's sarcoma: a study on safety and efficacy in AIDS patients [abstract]
121. Liposomal daunorubicin (DaunoXome) in the treatment of advanced AIDS-related Kaposi's sarcoma: results of a phase II study [abstract]
122. Phase II study of liposomal daunorubicin (DaunoXome) in AIDS related Kaposi sarcoma [abstract]
123. Epipodophyllotoxins in AIDS-related Kaposi's sarcoma: the SOAD experience [abstract]
124. Oral etoposide in AIDS-related Kaposi's sarcoma: a phase II trial [abstract]
125. Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma
126. The influence of antiretroviral therapy and chemoprophylaxis on the pattern of HIV associated diseases in the Swiss HIV Cohort Study [abstract]
127. Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma
128. Recombinant interferon-beta in the therapy of advanced AIDS-related Kaposi's sarcoma [abstract]
129. Recombinant interferon-alfa treatment in advanced KS and chronic HBV hepatitis associated with HIV infection [abstract]
130. In vitro inhibition of AIDS-related Kaposi's sarcoma by interferon and NK cell mediated cytotoxicity [abstract]
131. A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies
132. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma
133. Randomized study of 3 different dosages of interferon (INF) alpha 2 B for well-responding AIDS-related Kaposi's sarcoma (KS) [abstract]
134. The use of interferon alpha with antiretrovirals in AIDS patients with Kaposi's sarcoma and low T4 cell counts [abstract]
135. Interferon A 2b (IFNa 2b) versus monochemotherapy in AIDS-related Kaposi sarcoma (KS) [abstract]
136. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma
137. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma
138. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma
139. Natural antibodies to interferon-gamma (IFN-gamma) in endemic and epidemic Kaposi's sarcoma (KS) [abstract]
140. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS
141. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies
142. Treatment of AIDS associated Kaposi's sarcoma with an anti-IL6 monoclonal antibody [abstract]
143. Phase I/II evaluation of an IL-2 receptor targeted fusion toxin, DAB486IL-2, for treatment of AIDS-associated Kaposi's sarcoma [abstract]
144. Impact of CD8+ cellular therapy with concomitant IL-2 administration on the peripheral blood lymphocyte composition in AIDS patients with Kaposi's sarcoma [abstract]
145. All-transretinoic acid (TRA) in the treatment of AIDS-related Kaposi's sarcoma [abstract]
146. Systemic treatment of AIDS associated Kaposi's sarcoma (KS) with all-trans retinoic acid (ATRA) [abstract]
147. Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex
148. Effect of the alkaloid derivative UKRAIN in AIDS patients with Kaposi's sarcoma [abstract]
149. Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients
150. Prognostic factors of survival in a retrospective study of 200 Kaposi's sarcoma (KS) [abstract]
151. Relationship and prognostic value of endogenous interferon-alpha, beta 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS